Mesenchymal Stem Cells Therapy for Coronavirus COVID-19 Induced ARDS: A Promising Concept

Novel coronavirus severe acute respiratory syndrome (SARS)-CoV-2 pandemic has devastated the world causing an enormous health and financial crisis like none seen before. As many physicians and scientists fight to find a cure and vaccine, the virus continues to spread unchecked with a high mortality rate. Pulmonary involvement and development of severe acute respiratory distress syndrome (ARDS) have been some of the main contributors of mortality and morbidity in SARS-CoV-2 infection. Mesenchymal stem cells (MSC) have gained clinical interest as a treatment option due to their immunomodulatory and antifibrotic properties. Due to the emerging need to find treatment options, multiple MSC clinical trials are undergoing. Cellular treatment may represent a viable option for the treatment of ARDS and coronavirus infection.